Advances in™: What Does the Future Hold for Treatment of CML Along Lines of Care?

Release Date: July 27, 2021
Expiration Date: July 27, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of chronic myeloid leukemia (CML), with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of molecular testing, clinical trial data, current and emerging treatment strategies, and management of treatment-related toxicities will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Target Audience

This educational program is directed toward hematologists and medical oncologists interested in the treatment of hematologic malignancies. Other allied healthcare professionals, including nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with hematologic malignancies will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the role of clinical and cytogenic characteristics on risk stratification and treatment planning for the management of CML
• Assess the rationale for, as well as efficacy and safety data from ongoing clinical trials evaluating emerging therapies for the treatment of CML
• Apply methods to personalize decisions for patients with CML who may require switching based on risk for relapse, performance status, and treatment-related toxicities

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Michael J. Mauro, MD
Leader, Myeloproliferative Neoplasms Program
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Novartis, Bristol Myers Squibb, Sun Pharma/SPARC; Consultant: Novartis, Bristol Myers Squibb, Takeda, Pfizer.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.